ABSTRACT
INTRODUCTION
The pyrrolo[2, 1-c][ 1 ,4] benzodiazepines (PBDs, Figure 1 ) are a family of sequence-selective DNA-binding antitumour antibiotics that bind exclusively to the exocyclic N2 of guanine in the minor groove of DNA ( Figure 2 ) (1-2). These molecules possess an (S)-configuration at the chiral C1 la-position which provides them with a right-handed twist when viewed from the A-ring towards the C-ring. This feature provides the appropriate threedimensional shape for isohelicity with the minor groove of Bform DNA, leading to a snug fit at the binding site. Well known members of the PBD family include anthramycin, tomaymycin, DC-81, neothramycin and sibiromycin. Footprinting-type studies have shown that the adducts span 3 base-pairs with a rank order of preference for 5'-Pu-G-Pu > 5'-Pu-G-Py or 5'-Py-G-Pu > 5'-Py-G-Py sequences (2) (3) (4) . Recent high-field NMR and molecular modelling studies have provided detailed information about the precise three-dimensional structure of some PBDadducts, including orientation of the molecule in the groove and stereochemistry at the Cl 1-position (2) . So far, there is little understanding of the relationship between DNA-binding affinity, sequence-selectivity, and either in vitro cytotoxicity or in vivo antitumour activity. This is due, in part, to the lack of a sensitive and biologically relevant assay to compare the binding affinities of known PBDs. Although thermal denaturation (5) and ethidium bromide displacement (6) assays (ATm and EB60, respectively) have been useful in providing data, they are not sensitive enough to discriminate between weakly binding compounds of similar structure witiin this family.
The principle of inhibiting a restriction endonuclease by DNAinteracting ligands as a means to evaluate relative DNA-binding affinity has been investigated by a number of groups; for example cis-platin (7) and peptide nucleic acid chimeras (8) have been studied. Inhibition of restriction endonucleases by a PBD was originally established by Sumner and Bennet (9) , who demonstrated significant inhibition with anthramycin. However, the relationship between the concentration of anthramycin and the degree of inhibition was not investigated, and it was not clear from the study whether the effect was unique to anthramycin or was a general effect with other members of the PBD family. In this study, several members of the PBD family of various structure have been investigated for their ability to inhibit endonuclease cleavage activity, and a concentration dependence has been established for the inhibition.
MATERIALS AND METHODS
Anthramycin and tomaymycin methyl ethers, neothramycins A and B (3-0-butyl ethers) and sibiromycin were gifts from Hoffimann-La Roche Corporation (New Jersey, USA), Fujisawa Corporation (Ibaraki, Japan), the Institute of Microbial Chemistry (Tokyo, Japan), and Kyowa Hakko Kogyo Co. Ltd (Tokyo, Japan), respectively. DC-81 and iso-DC-81 were synthesised in this laboratory (10, 11) . Stock solutions of the PBD (1mM) were prepared by dissolving each compound in the minimmum amount of methanol (Aldrich, HPLC grade) before making up to volume with sterile water. All solutions were stored at 4°C. Methanol concentrations greater than 8%v/v were found to inhibit restriction endonuclease activity; therefore, this concentration of co-solvent was not exceeded in final stock solutions. pBR322 plasmid transformed into E. coli was supplied by Dr K.Firman (Biophysics Department, University of Portsmouth, UK). Cells bearing the plasmid were grown, amplified with ampicillin (20,ug/ml), the DNA isolated by alkaline lysis, and then purified by treatment with RNase A, phenol extraction, polyethyleneglycol (PEG) 8000 precipitation and ethanol precipitation (12 
RESULTS
The principle of the RED0OO assay is based upon the ability of a PBD to inhibit the cleavage activity of restriction endonuclease BamHI. Figure 3A shows a partial sequence (350-400 bp) of pBR322 with the preferred PBD (5'-Pu-G-Pu), BamHI (5'-GG-ATCC) and SspI (5'-AATATT) binding sites located by the DNAstar programme (13 extrapolated values for 100% inhibition avoids any problems associated with crossed linear regression plots. The significance of the slope value for each PBD is not fully understood, although it is suggested that differences may reflect other competitive binding modes. Inhibition experiments for the PBDs ( Figure 5 ) show a clear rank order of inhibition of cleavage: sibiromycin > anthramycin > tomaymycin > DC-81 > neothramycin > iso-DC-81 in terms of RED0oo value. This rank order of inhibition is identical to that observed for DNA-PBD binding as measured by ATm and EB60 studies for sibiromycin, anthramycin and tomaymycin (Table 1) . Interestingly, neither of the latter spectrophotometric methods is able to discriminate between DC-81, iso-DC-81 and neothramycin, presumably due to the similarity in the ability of these molecules to stabilize the double-stranded helix, a process that depends mainly on the strength of hydrogen bonding and van der Waals interactions between the PBD and DNA bases in the minor groove. However, DC-81 was shown to have an approximately 1.5-fold greater REDIoo value compared to neothramycin, and an approximately two-fold difference between DC-81 and iso-DC-81 was observed ( The DNA-binding data provided by this assay highlight a number of features of interest concerning structure-activity relationships (SARs) for the PBDs. First, the least cytotoxic molecules, DC-81, neothramycin and iso-DC-81, with the lowest relative DNA-binding affinities, all possess imine functionalities at the N0O-C1 1 position. Furthermore, these three compounds it has been previously shown that neothramycin is more electrophilic at Cll than compounds such as anthramycin or tomaymycin that contain carbinolamine methyl ether functions at N10-Cll (14) .
The three most potent compounds have in common an sp2-hybridized C2 carbon (Figure 1 
